Japan· JP-4291437A1028
ダラツムマブ（遺伝子組換え）
A daratumumab product containing ダラツムマブ（遺伝子組換え）, registered in Japan by ヤンセンファーマ, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Daratumumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FC01 (daratumumab), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 8 of them publish a price we can compare per daily dose
Daratumumab · ATC L01FC01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ダラツムマブ（遺伝子組換え）
- Manufacturer
- ヤンセンファーマ
- Country
- Japan (JP)
- ATC code
- L01FC01
- ATC class
- Daratumumab
- Defined daily dose
- 64.3 mg, P
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
72 interactions on record for daratumumab.
Graded by severity as the source publishes them — 29 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Daratumumab · interactions on record
72 records
- 29 severe
- 43 moderate
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Daratumumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainDARZALEX 1.800 MG SOLUCION INYECTABLEJanssen-Cilag International N.V
- United StatesDARZALEXJanssen Biotech, Inc.
- FinlandDarzalexOrifarm Oy
- BelgiumDarzalex 1800 mgJanssen-Cilag International
- CzechiaDARZALEXJanssen-Cilag International N.V., Beerse
- SwitzerlandDarzalex
- United KingdomDarzalex 100mg/5ml concentrate for solution for infusion vialsJanssen-Cilag Ltd
- NetherlandsDarzalex 1 800 mg oplossing voor injectieJanssen-Cilag International NV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Darzalex
- Liechtenstein · Darzalex
- Norway · Darzalex
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cb2328a3-84bb-4505-882a-d70a1091c77e GET /v1/drugs/cb2328a3-84bb-4505-882a-d70a1091c77e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１００ｍｇ５ｍＬ１瓶",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4291437A1028",
"category": "注射薬",
"price_yen": 52262,
"generic_name": "ダラツムマブ（遺伝子組換え）",
"product_name_jp": null,
"therapeutic_class": "4291",
"transitional_expiry": null
}See everything about daratumumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.